Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: SWITZERLAND

Sector: Biotechnology

CRISPR Therapeutics AG is a bio-technology company. The Company researches, develops, and manufactures biological transformative gene-based medicines and other related products. CRISPR Therapeutics operates in Switzerland.
Website: crisprtx.com


  • Good financial results growth rate 100.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (32.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -44.0% (LTM)
  • Share price is 74.8% higher than minimum and 38.7% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $9.6 mln (-0.211% of cap.)

Key Financials (Download financials)

Ticker: CRSP
Share price, USD:  (0.0%)54.65
year average price 51.31  


year start price 49.72 2025-02-15

min close price 31.27 2025-04-08

max close price 76.78 2025-10-08

current price 54.65 2026-02-14
Common stocks: 78 021 520

Dividend Yield:  0.0%
EV / Sales: 23.9x
Margin (EBITDA LTM / Revenue): -271.2%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 4 264
Net Debt ($m): -200
EV (Enterprise Value): 4 064
EBITDA LTM (млн $): -461
Price to Book: 2.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-03zacks.com

CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?

2026-02-02zacks.com

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing

2026-01-26zacks.com

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

2026-01-23zacks.com

CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors

2026-01-15zacks.com

CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors

2026-01-14seekingalpha.com

Crispr Therapeutics: Patience And Opportunity Through Volatility

2026-01-12seekingalpha.com

CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-12globenewswire.com

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

2026-01-02seekingalpha.com

Crispr Therapeutics: Prospects For 2026 - Why I Believe Casgevy Is Key

2025-12-31benzinga.com

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-10 2025-08-04 2024-11-05 2024-08-05 2024-05-08 2023-11-06 2023-08-07 2023-05-08 2022-11-01
acceptedDate 2025-11-10 08:15:47 2025-08-04 16:30:24 2025-02-11 16:10:29 2024-11-05 09:10:55 2024-08-05 16:10:26 2024-05-08 16:20:38 2024-02-21 07:50:50 2023-11-06 16:42:03 2023-08-07 16:12:38 2023-05-08 16:11:26 2023-02-21 16:11:51 2022-11-01 16:12:27 2022-02-15 16:14:44 2021-02-16 16:14:56
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 889 000 0 35M 602 000 517 000 504 000 370M 0 70M 100M 436 000 94 000 913M 719 000
costOfRevenue 65M 45M 110M 11M 57M 52M 130M 23M 45M 42M 110M 39M 101M 269M
grossProfit -64M -45M -75M -11M -56M -51M 240M -23M 25M 58M -110M -39M 812M -269M
grossProfitRatio -71.771 0 -17.527 -109.205 -101.776 0 0.362 0.578 -412.394
researchAndDevelopmentExpenses 59M 166M 321M 82M 75M 71M 387M 91M 102M 100M 462M 117M 341M 221M
generalAndAdministrativeExpenses 17M 19M 73M 17M 19M 18M 76M 18M 19M 22M 102M 27M 100M 86M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 17M 19M 73M 17M 19M 18M 76M 18M 19M 22M 102M 27M 100M 86M
otherExpenses -8M -892 000 -2M 0 26M 25M -1M 21M 18M 13M -762 000 0 -2M -221M
operatingExpenses 68M 184M 391M 100M 95M 89M 462M 109M 121M 122M 563M 144M 438M 86M
costAndExpenses 133M 229M 502M 111M 152M 141M 593M 132M 165M 164M 674M 182M 540M 355M
interestIncome 0 0 0 0 0 0 0 21M 0 0 0 0 0 0
interestExpense 0 0 0 0 0 0 0 0 0 -18M 0 -7M 0 0
depreciationAndAmortization 4M 5M 19M 5M 5M 5M 20M 5M 5M 5M 24M 5M 18M 9M
ebitda -101M -225M -447M -105M -146M -136M -203M -132M -90M -64M -649M -177M 391M -345M
ebitdaratio -114.048 0 -175.068 -283.201 -269.353 0 -1.289 -0.645 -1886.915
operatingIncome -132M -229M -467M -110M -151M -141M -223M -132M -95M -64M -673M -182M 374M -354M
operatingIncomeRatio -148.548 0 -182.94 -292.573 -278.942 0 -1.36 -0.645 -1940.298
totalOtherIncomeExpensesNet 26M 22M 104M 25M 26M 25M 72M 21M 18M 13M 23M 7M 6M 6M
incomeBeforeTax -106M -207M -363M -85M -125M -116M -151M -112M -77M -52M -651M -175M 380M -348M
incomeBeforeTaxRatio -119.035 0 -141.306 -242.014 -229.895 0 -1.097 -0.517 -1863.021
incomeTaxExpense 619 000 1M 4M 876 000 1M 724 000 3M -412 000 923 000 1M -325 000 -575 000 2M 809 000
netIncome -106M -209M -366M -86M -126M -117M -154M -112M -78M -53M -650M -175M 378M -349M
netIncomeRatio -119.731 0 -142.761 -244.503 -231.331 0 -1.111 -0.531 -1856.904
eps -1.17 -2.4 -4.34 -1.01 -1.49 -1.43 -1.94 -1.41 -0.98 -0.67 -8.36 -2.24 4.97 -5.29
epsdiluted -1.17 -2.4 -1.01 -1.49 -1.43 -1.41 -0.98 -0.67 -2.24
weightedAverageShsOut 91M 87M 84M 85M 85M 82M 79M 79M 79M 79M 78M 78M 76M 66M
weightedAverageShsOutDil 91M 87M 84M 85M 85M 82M 79M 79M 79M 79M 78M 78M 80M 66M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-11 2024-02-21 2023-02-21 2022-02-15 2021-02-16
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 0 0 0 0 0
ebit -467M -223M -673M 374M -354M
nonOperatingIncomeExcludingInterest 0 0 0 0 0
netIncomeFromContinuingOperations -366M -154M -650M 378M -349M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -366M -154M -650M 378M -349M
epsDiluted -4.34 -1.94 -8.36 4.7 -5.29

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-10 2025-08-04 2024-11-05 2024-08-05 2024-05-08 2023-11-06 2023-08-07 2023-05-08 2022-11-01
acceptedDate 2025-11-10 08:15:47 2025-08-04 16:30:24 2025-02-11 16:10:29 2024-11-05 09:10:55 2024-08-05 16:10:26 2024-05-08 16:20:38 2024-02-21 07:50:50 2023-11-06 16:42:03 2023-08-07 16:12:38 2023-05-08 16:11:26 2023-02-21 16:11:51 2022-11-01 16:12:27 2022-02-15 16:14:44 2021-02-16 16:14:56
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 286M 197M 298M 226M 484M 707M 389M 528M 445M 344M 212M 494M 923M 1 169M
shortTermInvestments 1 629M 1 528M 1 606M 1 710M 1 517M 1 401M 1 304M 1 212M 1 323M 1 539M 1 603M 1 402M 1 456M 522M
cashAndShortTermInvestments 1 916M 1 725M 1 904M 1 936M 2 002M 2 108M 1 694M 1 740M 1 768M 344M 1 815M 1 896M 2 379M 1 690M
netReceivables 0 0 25M 0 0 0 200M 0 70M 0 0 49 000 305 000 11M
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 13M 9M 8M 8M 9M 11M 7M 21M 21M 25M 12M 37M 8M 0
totalCurrentAssets 1 929M 1 734M 1 937M 1 944M 2 010M 2 120M 1 908M 1 761M 1 860M 1 908M 1 853M 1 933M 2 418M 1 717M
propertyPlantEquipmentNet 255M 263M 278M 285M 292M 299M 306M 312M 319M 316M 321M 328M 312M 93M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 2000 16 000 30 000 43 000 57 000 71 000 84 000 125 000 180 000
goodwillAndIntangibleAssets 0 0 0 0 0 2000 16 000 30 000 43 000 57 000 71 000 84 000 125 000 180 000
longTermInvestments 28M 31M 0 0 23M 12M 2M 12M 5M 6M 53M 77M 0 0
taxAssets 0 0 0 0 0 -12M 0 -12M 0 0 0 0 0 0
otherNonCurrentAssets 32M 3M 27M 27M 15M 21M 14M 14M 14M 14M 16M 16M 22M 18M
totalNonCurrentAssets 316M 296M 305M 312M 329M 319M 321M 326M 337M 336M 390M 421M 334M 111M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 2 245M 2 030M 2 242M 2 256M 2 340M 2 439M 2 230M 2 087M 2 197M 2 244M 2 243M 2 353M 2 752M 1 828M
accountPayables 12M 10M 15M 16M 9M 16M 38M 26M 28M 45M 27M 32M 15M 9M
shortTermDebt 18M 18M 17M 34M 33M 16M 16M 15M 15M 16M 16M 11M 12M 11M
taxPayables 3M 715 000 451 000 838 000 454 000 1M 0 176 000 558 000 273 000 0 4M 0 10M
deferredRevenue 1M 2M 4M 4M 5M 4M 4M 4M 12M 12M 0 12M 1M 2M
otherCurrentLiabilities 84M 74M 33M 35M 80M 82M 33M 67M 78M 74M 58M 95M 68M 39M
totalCurrentLiabilities 119M 104M 88M 90M 128M 119M 109M 111M 133M 147M 121M 151M 120M 94M
longTermDebt 193M 197M 0 211M 215M 219M 0 227M 230M 225M 0 231M 0 0
deferredRevenueNonCurrent 12M 12M 12M 12M 13M 14M 14M 16M 12M 12M 12M 12M 12M 12M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 5M 4M 3M 4M 4M 4M 957 999 5M 5M 6M 6M 193M 7M 8M
totalNonCurrentLiabilities 210M 214M 222M 227M 231M 236M 238M 248M 248M 243M 246M 249M 233M 69M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 193M 197M 206M 228M 231M 219M 223M 242M 245M 240M 228M 242M 213M 50M
totalLiabilities 329M 319M 310M 316M 359M 355M 347M 359M 381M 389M 368M 399M 352M 164M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 3M 3M 3M 3M 3M 3M 2M 2M 2M 2M 2M 2M 2M 2M
retainedEarnings -1 817M -1 710M -1 366M -1 329M -1 243M -1 116M -1 000M -1 089M -977M -899M -846M -736M -196M -574M
accumulatedOtherComprehensiveIncomeLoss 5M 4M 2M 11M -3M -2M 2M -7M -9M -9M -16M -22M -5M -83 000
othertotalStockholdersEquity 3 725M 3 415M 3 255M 3 224M 3 199M 2 821M 2 799M 2 761M 2 709M
totalStockholdersEquity 1 916M 1 711M 1 932M 1 940M 1 981M 2 084M 1 883M 1 728M 1 816M 1 855M 1 875M 1 954M 2 399M 1 664M
totalEquity 1 916M 1 711M 1 932M 1 940M 1 981M 2 084M 1 883M 1 728M 1 816M 1 855M 1 875M 1 954M 2 399M 1 664M
totalLiabilitiesAndStockholdersEquity 2 245M 2 030M 2 256M 2 340M 2 439M 2 087M 2 197M 2 244M 2 353M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 2 245M 2 030M 2 242M 2 256M 2 340M 2 439M 2 230M 2 087M 2 197M 2 244M 2 243M 2 353M 2 752M 1 828M
totalInvestments 1 658M 1 558M 1 606M 1 710M 1 540M 1 412M 1 306M 1 212M 1 328M 1 545M 1 657M 1 479M 1 456M 522M
totalDebt 211M 215M 224M 228M 231M 235M 239M 242M 245M 240M 244M 242M 225M 61M
netDebt -75M 18M -75M 2M -253M -473M -151M -286M -200M -104M 32M -252M -698M -1 107M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-11 2024-02-21 2023-02-21 2022-02-15 2021-02-16
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 25M 200M 0 305 000 144 000
otherReceivables 0 0 0 0 11M
prepaids 0 8M 26M 30M 15M
totalPayables 15M 39M 28M 16M 20M
otherPayables 451 000 438 000 135 000 724 000 10M
accruedExpenses 18M 17M 19M 24M 22M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 206M 223M 228M 213M 50M
treasuryStock -62 000 -62 000 -63 000 -63 000 -63 000
additionalPaidInCapital 3 294M 2 878M 2 735M 2 598M 2 236M
otherTotalStockholdersEquity 0 1 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-10 2025-08-04 2024-11-05 2024-08-05 2024-05-08 2023-11-06 2023-08-07 2023-05-08 2022-11-01
acceptedDate 2025-11-10 08:15:47 2025-08-04 16:30:24 2025-02-11 16:10:29 2024-11-05 09:10:55 2024-08-05 16:10:26 2024-05-08 16:20:38 2024-02-21 07:50:50 2023-11-06 16:42:03 2023-08-07 16:12:38 2023-05-08 16:11:26 2023-02-21 16:11:51 2022-11-01 16:12:27 2022-02-15 16:14:44 2021-02-16 16:14:56
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -106M -209M -366M -86M -126M -117M -154M -112M -78M -53M -650M -175M 378M -349M
depreciationAndAmortization 4M 5M 19M 5M 5M 5M 20M 5M 5M 5M 24M 5M 18M 9M
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 17M 18M 87M 22M 24M 19M 81M 20M 22M 21M 98M 25M 102M 66M
changeInWorkingCapital 11M -17M 156M -40M 10M 210M -194M 53M -79M 37M 20M 37M 27M 33M
accountsReceivables 0 0 175M 0 0 200M -200M 70M -70M 0 305 000 17 000 -161 000 -45 000
inventory 0 0 0 0 0 0 0 25M 12M 0 0 0 -38M -26M
accountsPayables 0 -15M 0 -38M 9M 9M -20M -25M -12M 25M 5M 0 38M 26M
otherWorkingCapital 11M -2M -19M -2M 1M 1M 27M -17M 2M 12M 14M 37M 27M 33M
otherNonCashItems -10M 89M -39M -7M 16M -189M -14M -5M -3M -969 000 12M 3M 14M 2M
netCashProvidedByOperatingActivities -85M -114M -143M -107M -96M 110M -260M -40M -133M 9M -496M -105M 539M -238M
investmentsInPropertyPlantAndEquipment -74 000 -117 000 -2M -219 000 -707 000 -721 000 -9M -2M -4M -3M -37M -6M -82M -18M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 221M 0 954M 523M
purchasesOfInvestments -334M -215M -1 486M -389M -476M -334M -1 066M -245M -187M -266M -1 418M -326M -1 509M -594M
salesMaturitiesOfInvestments 215M 310M 1 208M 248M 350M 237M 1 453M 370M 409M 387M 1 196M 420M 556M 71M
otherInvestingActivites 0 -25M -20M -126M -8M -1 000 000 -2M 0 0
netCashUsedForInvestingActivites -119M 70M -162M -127M -98M 121M 217M 118M 87M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 278M 2M 6M -1M 306M 2M 17M 0 970 000
commonStockRepurchased 0 0 0 466 000 -466 000 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 19M 0 4M 546 000 306M 2M 0 5M 14M
netCashUsedProvidedByFinancingActivities 297M 2M 10M -466 000 306M 2M 17M 5M 15M
effectOfForexChangesOnCash -27 000 80 000 -21 000 75 000 2000 -11 000 656 000 -48 000 28 000 32 000 -80 000 -100 000 -11 000 40 000
netChangeInCash 93M -42M -91M -247M -223M 318M 178M 83M 100M 132M -716M -3M -246M 237M
cashAtEndOfPeriod 298M 197M 310M 237M 484M 707M 389M 540M 457M 356M 224M 510M 940M 1 185M
cashAtBeginningOfPeriod 205M 239M 401M 484M 707M 389M 212M 457M 356M 224M 940M 513M 1 185M 949M
operatingCashFlow -85M -114M -143M -107M -96M 110M -260M -40M -133M 9M -496M -105M 539M -238M
capitalExpenditure -74 000 -117 000 -2M -219 000 -707 000 -721 000 -9M -2M -4M -3M -37M -6M -82M -18M
freeCashFlow -85M -114M -145M -107M -96M 109M -270M -42M -137M 6M -533M -111M 457M -257M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-11 2024-02-21 2023-02-21 2022-02-15 2021-02-16
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 -3M -221M -954M -523M
netCashProvidedByInvestingActivities -280M 375M -259M -1 035M -541M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 301M 63M 970 000 213M 982M
netCommonStockIssuance 301M 63M 970 000 213M 982M
commonStockIssuance 301M 63M 970 000 213M 982M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 31M 0 38M 38M 34M
netCashProvidedByFinancingActivities 332M 63M 39M 251M 1 016M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 10
2025-11-10 08:15 ET
CRISPR Therapeutics reported for 2025 q3
SEC form 8
2025-11-10 08:10 ET
CRISPR Therapeutics published news for 2025 q3
SEC form 8
2025-11-10 08:10 ET
CRISPR Therapeutics reported for 2025 q3
SEC form 8
2025-10-15 20:18 ET
CRISPR Therapeutics published news for 2025 q3
SEC form 8
2025-10-15 20:18 ET
CRISPR Therapeutics published news for 2025 q3
SEC form 10
2025-08-04 20:30 ET
CRISPR Therapeutics reported for 2025 q2
SEC form 8
2025-08-04 20:21 ET
CRISPR Therapeutics published news for 2025 q2
SEC form 8
2025-08-04 20:21 ET
CRISPR Therapeutics reported for 2025 q2
SEC form 8
2025-05-19 20:36 ET
CRISPR Therapeutics published news for 2025 q1
SEC form 8
2025-05-19 20:36 ET
CRISPR Therapeutics published news for 2025 q1
SEC form 8
2025-05-19 20:36 ET
CRISPR Therapeutics published news for 2025 q1
SEC form 10
2025-05-06 20:10 ET
CRISPR Therapeutics reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
CRISPR Therapeutics reported for 2025 q1
SEC form 8
2025-05-06 00:00 ET
CRISPR Therapeutics published news for 2025 q1
SEC form 8
2025-05-06 00:00 ET
CRISPR Therapeutics reported for 2025 q1
SEC form 10
2025-02-11 21:10 ET
CRISPR Therapeutics reported for 2024 q4
SEC form 10
2025-02-11 00:00 ET
CRISPR Therapeutics reported for 2024 q4
SEC form 8
2025-02-11 00:00 ET
CRISPR Therapeutics published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
CRISPR Therapeutics reported for 2024 q4
SEC form 10
2024-11-05 09:10 ET
CRISPR Therapeutics reported for 2024 q3
SEC form 8
2024-11-05 09:05 ET
CRISPR Therapeutics published news for 2024 q3
SEC form 8
2024-11-05 09:05 ET
CRISPR Therapeutics reported for 2024 q3
SEC form 10
2024-08-05 16:10 ET
CRISPR Therapeutics reported for 2024 q2
SEC form 8
2024-08-05 16:05 ET
CRISPR Therapeutics published news for 2024 q2
SEC form 8
2024-08-05 16:05 ET
CRISPR Therapeutics reported for 2024 q2
SEC form 10
2024-08-05 00:00 ET
CRISPR Therapeutics reported for 2024 q2
SEC form 10
2024-05-08 16:20 ET
CRISPR Therapeutics reported for 2024 q1
SEC form 8
2024-05-08 16:15 ET
CRISPR Therapeutics published news for 2024 q1
SEC form 8
2024-05-08 16:15 ET
CRISPR Therapeutics reported for 2024 q1
SEC form 10
2024-05-08 00:00 ET
CRISPR Therapeutics reported for 2024 q1
SEC form 10
2024-02-21 07:50 ET
CRISPR Therapeutics reported for 2023 q4
SEC form 8
2024-02-21 07:45 ET
CRISPR Therapeutics published news for 2023 q4
SEC form 8
2024-02-21 07:45 ET
CRISPR Therapeutics reported for 2023 q4
SEC form 10
2024-02-21 00:00 ET
CRISPR Therapeutics reported for 2023 q4
SEC form 10
2023-11-06 16:42 ET
CRISPR Therapeutics reported for 2023 q3
SEC form 8
2023-11-06 16:33 ET
CRISPR Therapeutics published news for 2023 q3
SEC form 10
2023-11-06 00:00 ET
CRISPR Therapeutics reported for 2023 q3
SEC form 10
2023-08-07 16:12 ET
CRISPR Therapeutics reported for 2023 q2
SEC form 6
2023-08-07 16:07 ET
CRISPR Therapeutics reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
CRISPR Therapeutics reported for 2023 q2
SEC form 8
2023-08-07 00:00 ET
CRISPR Therapeutics reported for 2023 q2
SEC form 6
2023-06-09 17:56 ET
CRISPR Therapeutics published news for 2023 q1
SEC form 6
2023-06-09 16:29 ET
CRISPR Therapeutics published news for 2023 q1
SEC form 6
2023-06-09 07:07 ET
CRISPR Therapeutics published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
CRISPR Therapeutics reported for 2023 q1
SEC form 8
2023-05-08 00:00 ET
CRISPR Therapeutics reported for 2023 q1
SEC form 6
2023-04-03 08:10 ET
CRISPR Therapeutics published news for 2023 q1
SEC form 6
2023-03-29 08:08 ET
CRISPR Therapeutics published news for 2022 q4
SEC form 6
2023-03-27 08:08 ET
CRISPR Therapeutics published news for 2022 q4
SEC form 6
2023-03-14 17:42 ET
CRISPR Therapeutics published news for 2022 q4
SEC form 6
2023-03-14 08:15 ET
CRISPR Therapeutics published news for 2022 q4
SEC form 10
2023-02-21 16:11 ET
CRISPR Therapeutics reported for 2022 q4
SEC form 6
2023-02-21 16:06 ET
CRISPR Therapeutics reported for 2022 q4
SEC form 10
2023-02-21 00:00 ET
CRISPR Therapeutics reported for 2022 q4
SEC form 8
2023-02-21 00:00 ET
CRISPR Therapeutics reported for 2022 q4
SEC form 10
2022-11-01 16:12 ET
CRISPR Therapeutics published news for 2022 q3
SEC form 6
2022-11-01 16:05 ET
CRISPR Therapeutics published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
CRISPR Therapeutics reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
CRISPR Therapeutics reported for 2022 q3
SEC form 6
2022-10-27 08:36 ET
CRISPR Therapeutics published news for 2022 q3
SEC form 6
2022-09-27 07:48 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 6
2022-08-18 17:39 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 6
2022-08-18 17:36 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 6
2022-08-18 17:33 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 10
2022-08-08 08:11 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 6
2022-08-08 08:05 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 10
2022-08-08 00:00 ET
CRISPR Therapeutics reported for 2022 q2
SEC form 8
2022-08-08 00:00 ET
CRISPR Therapeutics reported for 2022 q2
SEC form 6
2022-06-21 17:05 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-13 16:58 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-13 08:02 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:44 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:43 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:41 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:39 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:36 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:35 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:33 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-05-23 17:41 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-05-16 16:14 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-05-12 16:05 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 10
2022-05-09 16:12 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-05-09 16:06 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 10
2022-05-09 00:00 ET
CRISPR Therapeutics reported for 2022 q1
SEC form 8
2022-05-09 00:00 ET
CRISPR Therapeutics reported for 2022 q1
SEC form 6
2022-04-25 16:23 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-04-12 16:28 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 10
2022-02-15 16:14 ET
CRISPR Therapeutics published news for 2021 q4
SEC form 6
2022-02-15 16:05 ET
CRISPR Therapeutics published news for 2021 q4
SEC form 10
2022-02-15 00:00 ET
CRISPR Therapeutics published news for 2021 q4
SEC form 8
2022-02-15 00:00 ET
CRISPR Therapeutics published news for 2021 q4
SEC form 6
2021-12-20 08:00 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 6
2021-11-22 08:42 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 10
2021-11-03 16:11 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 6
2021-11-03 16:07 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 6
2021-10-14 07:15 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 6
2021-10-12 16:46 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 10
2021-07-29 16:44 ET
CRISPR Therapeutics published news for 2021 q2
SEC form 6
2021-07-29 16:34 ET
CRISPR Therapeutics published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
CRISPR Therapeutics published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
CRISPR Therapeutics published news for 2021 q2
SEC form 6
2021-06-14 17:32 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-06-14 16:52 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-06-11 07:10 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-06-02 09:16 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-04-28 16:14 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 10
2021-04-27 16:19 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-04-27 16:05 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 10
2021-04-27 00:00 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 8
2021-04-27 00:00 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-04-20 07:22 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-04-05 16:18 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 10
2021-02-16 16:14 ET
CRISPR Therapeutics published news for 2020 q4
SEC form 6
2021-02-16 16:06 ET
CRISPR Therapeutics published news for 2020 q4
SEC form 6
2021-01-15 16:12 ET
CRISPR Therapeutics published news for 2020 q4
SEC form 6
2020-12-17 09:06 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 6
2020-12-11 08:16 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 6
2020-12-07 07:50 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 6
2020-11-04 09:14 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 10
2020-10-28 08:08 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 6
2020-10-28 08:03 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 6
2020-10-21 08:58 ET
CRISPR Therapeutics published news for 2020 q3